国药现代(600420.SH)：原料药阿戈美拉汀上市申请获批准

Core Viewpoint - The company Guoyao Modern (600420.SH) announced that its wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of the raw material drug Agomelatine [1] Group 1 - Agomelatine primarily acts by stimulating melatonin receptors MT1 and MT2 and antagonizing 5-HT2C, helping to restore disrupted biological rhythms and exerting antidepressant effects [1] - The formulation of Agomelatine is mainly used clinically for the treatment of adult depression [1]